GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Trial details

Who runs it

Genmab A/S

Trial code

EU 2022-502453-33-00

Record updated

2024. március 26.

Original description

Evaluate the antitumor activity of GEN1046 in combination with anticancer therapy in subjects with advanced endometrial cancerRead full original descriptionShow less

A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer

Evaluate the antitumor activity of GEN1046 in combination with anticancer therapy in subjects with advanced endometrial cancer

Inclusion: Have a histologically confirmed diagnosis of advanced (unresectable, recurrent, and/or metastatic) endometrial carcinoma that is incurable and for which prior standard first-line treatment has failed; Prior to C1D1, documentation of tumor dMMR/MSI-H status must be available based on previously performed mismatch repair (MMR)/microsatellite instability (MSI) testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next-generation sequencing (NGS) performed with a Food and Drug Administration (FDA)-approved/Conformitè Europëenne (CE)-marked test; Must have progressed on or after at least 1 (but no more than 2) prior line(s) of a systemic chemotherapy regimen for unresectable and/or metastatic endometrial cancer of which at least 1 regimen of platinum-based treatment unless subject is ineligible for or intolerant to platinum; Cohort A only: Must be treatment naive for CPIs including PD-1 or PD-L1 inhibitors and other immune CPIs (eg, anticytotoxic T-lymphocyte-associated protein 4 [CTLA-4], anti-lymphocyte-activation gene 3 [LAG3], anti-T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains [TIGIT]); Cohort B only: Must have received and progressed on or after prior treatment with a PD-1/PD-L1 inhibitor alone or in combination. Moreover, the subject must fulfill the following:Duration of CPI containing treatment and best overall response (BOR) is known, and subject has received a minimum of 2 cycles of CPI.

Exclusion: Has been exposed to any of the following prior therapies/treatments within the specified timeframes: • Any prior treatment with any type of antitumor vaccine or autologous cell immunotherapy. • Radiotherapy within 14 days before the planned first dose of trial treatment with exception of palliative radiotherapy to bone lesions, which is allowed if completed 7 days prior to trial treatment start. Participants must have recovered from all radiation-related toxicities and/or complications prior to enrollment and must have tapered corticosteroid treatment to ≤10 mg/day at the time of first dose. • Treatment with an anticancer agent, including investigational vaccines within 28 days before or 5 times t1/2, whichever is shorter, prior to the planned first dose of trial treatment or is currently enrolled in an interventional trial. Note: Subjects who are in the follow-up phase of an interventional trial may participate if the subject has not received the investigational agent within 28 days of the first dose of trial treatment. • Prior treatment with live, attenuated vaccines within 30 days prior to initiation of trial treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Experimental and/or nonauthorized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations are not allowed. • Received granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support within 4 weeks before the planned first dose of trial treatment; Cohort A only: Prior exposure to immune CPIs (eg, anti-PD-1/anti-PD-L1, anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg, 4-1BB, OX40); Cohort B only: • Known history of Grade 3 or higher irAEs that led to treatment discontinuation of a prior immunotherapy treatment • Exposure to any of the following prior therapies/treatments within the specified timeframes: • Prior exposure to immune CPIs other than anti-PD-1/anti-PD-L1 (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg, 4-1BB, OX40) • PD-1/PD-L1 antibody within 28 days before the planned first dose of trial treatment; Has carcinosarcoma, malignant mixed Műllerian tumor, endometrial leiomyosarcoma, or endometrial stromal sarcomas; Current pneumonitis (any grade) including any radiological change of ongoing pneumonitis at baseline or history of noninfectious drug-, immune-, or radiation-related pneumonitis that has required steroids.

EU CTIS 2022-502453-33-00